Trial Profile
Immunogenicity and reactogenicity of tgAAV 09 in volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2011
Price :
$35
*
At a glance
- Drugs TgAAC 09 (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors AmpliPhi Biosciences Corporation
- 29 Nov 2005 New trial record.